Industry News
Select Vaccines to raise $1.79m
Melbourne's Select Vaccines (ASX:SLT) is planning to raise AUD$1.79 million through a rights issue and placement to provide working capital for the development of a vaccine against hepatitis C and further development of diagnostic assays. [ + ]
US$1m milestone payment for BioDiem
Melbourne-based flu vaccine company BioDiem (ASX:BDM) has received a payment of US$1 million (AUD$1.35 million) from Akzo Nobel's Nobilon, bringing its total milestone payments to US$3 million. [ + ]
Unknown party lists Psiron on Berlin-Bremen stock exchange
The Berlin-Bremen stock exchange in Germany has advised Psiron (ASX:PSX) that a third party has applied for the Sydney-based oncology therapy developer's shares to be listed on Freiverkehr, the stock exchange's third market segment. [ + ]
Virax aims to raise $3.85m after NIH disappointment
Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has lodged a prospectus to raise AUD$3.85 million through a rights issue for the further development of its HIV therapeutic vaccine VIR201 following its unsuccessful bid for US NIH funding. [ + ]
Epitan CEO replaced, appoints CSO
Melbourne-based Epitan's (ASX:EPT, ADR:EPTNY, XETRA:UR9) CEO Iain Kirkwood has been replaced by Dr Philippe Wolgen, effective immediately. [ + ]
Cambridge research delves into memory
Animals as diverse as sea slugs, fruit flies, mice and humans can learn. But how memories are stored in the brain and then retrieved is still a mystery, and Australian researcher Prof Seth Grant is trying to solve it. [ + ]
Positive results for Peplin phase IIa 'sun spot' trial
Peplin (ASX:PEP) has reported positive results from its phase IIa clinical trial of its proprietary drug PEP005 Topical in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer. [ + ]
New professor of chemistry
A world leader in the application of nuclear magnetic resonance (NMR) spectroscopy, Robert Brownlee, has been appointed Professor of Chemistry at La Trobe University.
[ + ]APIA to broadcast live heart disease cases
Cardiologists and medical professionals will witness the biggest heart disease live case demonstration in Australian history at the inaugural Asia-Pacific Interventional Advances Conference (APIA), taking place 29 November to 2 December in Newcastle. [ + ]
Direct Capital acquires 51 per cent of New Zealand Pharmaceuticals
New Zealand based VC Direct Capital has acquired a shareholding of 51 per cent in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for pharmaceutical and biotechnology companies. [ + ]
Lack of understanding is holding back biotech: IPTA
A survey of biotechnology patent attorneys has indicated that there is a lack of knowledge within the general population about what biotechnology encompasses and there are misconceptions regarding the patenting process. [ + ]
Stem cell photo exhibition to tour Australia
A photo exhibition featuring images of stem cells in their various forms was opened today in Melbourne by Senator Natasha Stott Despoja. [ + ]
Further extensions sought in GTG/Applera dispute
Melbourne gene-test company Genetic Technologies (ASX: GTG; NASDAQ: GENE) US rival Applera Technologies have sought additional time from the US District Court of Northern California to resolve the long-running licensing dispute between the companies. [ + ]
CollTech granted patent
Perth collagen purification company CollTech (ASX:CAU) has been granted a patent by the Australian Patents Office. [ + ]
Leading anti-GM figure to tour Australia
Anti-GM NGO, the Australian GeneEthics Network, is hosting an Australian speaking tour by American Dr Chuck Benbrook, a prominent organic-food advocate and bete noire of genetically modified agriculture. [ + ]
